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Natural History of Vanishing White Matter
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Gerre Vermeulen, MD,1 Jan A. M. Gerver, MD,1 Charles M. Lourenço, MD,2
Sakkubai Naidu, MD,3 Hanna Mierzewska, MD, PhD,4 Reinoud J. B. J. Gemke, MD, PhD,5
Henrica C. W. de Vet, PhD,6 Bernard M. J. Uitdehaag, MD, PhD,7
Birgit I. Lissenberg-Witte, PhD,6 VWM Research Group,* and
Marjo S. van der Knaap, MD, PhD1,8
Objective: To comprehensively describe the natural history of vanishing white matter (VWM), aiming at improving
counseling of patients/families and providing natural history data for future therapeutic trials.
Methods: We performed a longitudinal multicenter study among 296 genetically conﬁrmed VWM patients. Clinical
information was obtained via disease-speciﬁc clinical questionnaire, Health Utilities Index and Guy’s Neurological Dis-
ability Scale assessments, and chart review.
Results: First disease signs occurred at a median age of 3 years (mode = 2 years, range = before birth to 54 years);
60% of patients were symptomatic before the age of 4 years. The nature of the ﬁrst signs varied for different ages of
onset. Overall, motor problems were the most common presenting sign, especially in children. Adolescent and adult
onset patients were more likely to exhibit cognitive problems early after disease onset. One hundred two patients were
deceased. Multivariate Cox regression analysis revealed a positive relation between age at onset and both preservation
of ambulation and survival. Absence of stress-provoked episodes and absence of seizures predicted more favorable
outcome. In patients with onset before 4 years, earlier onset was associated with more severe disability and higher
mortality. For onset from 4 years on, disease course was generally milder, with a wide variation in severity. There were
no signiﬁcant differences for sex or for the 5 eIF2B gene groups. The results conﬁrm the presence of a genotype–
phenotype correlation.
Interpretation: The VWM disease spectrum consists of a continuum with extremely wide variability. Age at onset is a
strong predictor for disease course.
ANN NEUROL 2018;84:274–288
Vanishing white matter (VWM; Online MendelianInheritance in Man database 603896) 1–3 is one of
the more prevalent leukodystrophies.4 It is caused by
recessive mutations in any of the genes EIF2B1–5.5,6
Patients typically have normal early development, followed
by chronic neurological deterioration and additionally
stress-provoked episodes of rapid decline.2 No curative
treatment is available.7 Although VWM was initially rec-
ognized as a disorder of young children,1,2,8 it has become
apparent that disease onset and severity vary widely, from
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antenatal or early infantile onset disease with rapid
demise9–11 to adult onset slow disease.3,12
Knowledge of the epidemiology and natural history
of VWM is essential for physicians to counsel patients and
families and make decisions on clinical management.
Additionally, natural history studies are valuable for
insight into pathomechanisms, genotype–phenotype corre-
lations, and setup of therapeutic trials. Natural history
studies in VWM are scarce and rather small.13–15 We
report results of a 12½-year natural history study of
VWM, focusing on occurrence of neurological signs in
relation to age and disease duration, identiﬁcation of prog-
nostic factors, and assessment of dimensions of disability
by 2 validated scales: Health Utilities Index (HUI) and
Guy’s Neurological Disability Scale (GNDS).
Patients and Methods
Study Design
Between January 2004 and October 2016, we performed
a multicenter longitudinal observational study on all
genetically proven VWM patients enrolled in the Amster-
dam Database of Leukoencephalopathies. The database
contains all VWM patients referred for mutational analysis
and proven to have biallelic mutations in the genes
EIF2B1–5 and 17 patients referred for magnetic resonance
imaging (MRI) analysis and genetically conﬁrmed else-
where.16 VWM patients with additional diseases affecting
neurological function were excluded. Written informed
consent was obtained from participating patients or guard-
ians. The study was approved by the ethics committee of
VU University Medical Center, Amsterdam.
Clinical Information
We obtained information on disease course by a custom-
ized disease-speciﬁc clinical questionnaire, completed by
the patient’s physician or the patient and/or family mem-
bers in consultation with the authors. If these sources were
not available, we performed retrospective chart review.
The questionnaire aimed at robust parameters that could
easily be assessed by physicians, also when reviewing
patient ﬁles retrospectively, and by parents. It involved
items on demographic details, pregnancy and delivery,
early motor development, early cognitive development,
disease onset and presenting signs, provoking factors, epi-
sodes of deterioration, disease course, neurological signs,
and survival. Data on medical history were obtained retro-
spectively when the patient entered the study. From then
on, data were collected prospectively, using the question-
naire, HUI scores from age 2 years, and GNDS scores
from age 8 years at 1 to 4 time points. HUI and GNDS
scores were assessed by proxies (physicians or parents), in
3 patients by self-assessment, using postal or digital forms,
telephone interviews, or in-person interviews. All data
were checked for internal consistency and consistency with
other data.
Patients were scored as having lost walking without
support when they could no longer walk without equip-
ment or the help of another person; they were scored as
having lost walking with or without support when fully
wheelchair dependent. To avoid introducing a bias by
omitting patients who were more seriously affected and
did not achieve walking, we scored patients who presented
before 18 months and never achieved walking as having
lost ambulation at disease onset and scored patients who
had mildly delayed early development and never achieved
walking but presented with signs of neurological deteriora-
tion later than 18 months as having lost ambulation at
18 months. Patients who died before 18 months or were
not followed until that age were not included in analyses
concerning ambulation. The disease course was deﬁned as
exacerbating if ≥1 episodes of acute major neurological
deterioration occurred. Ovarian failure was assessed in
females from 16 years at latest follow-up.
Health Utilities Index
HUI17 is a well-validated instrument to assess health status
and health-related quality of life (HRQL). It has been used
extensively as an outcome measure, also for neurological dis-
orders, in patients from age 1 year.18–21 It comprises distinct
attributes of health status that enable valuation of function-
speciﬁc scores (single-attribute utility scores) and generic
multiattribute preference-based measures of quality of life
(HUI Health Index) at a point in time. We applied the
HUIMark 3 (HUI3) proxy version, which comprises 8 attri-
butes: Vision, Hearing, Speech, Ambulation, Dexterity,
Emotion, Cognition, and Pain. Each attribute has 5 or
6 levels (Supplementary Table 1A) 17; single-attribute scores
range between 0 (severe impairment) and 1 (no impairment;
see Supplementary Table 1B). We measured 1 attribute of
the HUI Mark 2 (HUI2) on Self-Care. We used HUI deci-
sion tables to generate HUI2 and HUI3 single-attribute util-
ity scores22,23 and applied coding algorithms to obtain
overall HUI3 Health Index scores (see Supplementary
Table 1C).23 The latter represent the patient’s state on a
scale from 0 (equivalent to death) to 1 (equivalent to perfect
health). The minimum is a negative score (−0.36); all nega-
tive scores indicate a state rated “worse than dead” in the
preference survey among the general population.23 For miss-
ing data, we applied inspection and logical deduction
according to published guidelines.24 If > 2 attribute scores
were missing, the concerning inventory was excluded (1%
of inventories). We used hot deck imputation with pattern
similarity to impute the few remaining missing values up to
a maximum of 2 domains.24 Imputations were only
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calculated for the HUI3 attribute scores on Cognition in
3% of inventories and on Emotion in 1%.
To analyze the evolution of HUI scores over time,
we gave each patient a baseline score at disease onset, cor-
responding to the age-matched reference scores from
HUI3 reference population data.25,26 For individuals
younger than 5 years, for whom no reference scores are
available, we applied the reference score of 0.92 for age
5 years. For death, we used a score of −0.5, deviating from
score 0 of the HUI scale, because numerous patients had
negative scores during life, while being happy, as apparent
from Emotion scores, not in line with worse than dead.
Moreover, scores of such patients would otherwise rise
from below 0 during life to 0 at death. Changing death
status from 0 to −0.5 alters the meaning of the negative
scores but does not inﬂuence the statistical characteristics
of the scale. We gave deceased patients in whom no HUI
was obtained because of age < 2 years or nonresponse a
baseline score at onset and end score at death.
Guys Neurological Disability Scale
GNDS is a reliable measure to assess neurological disability,
created to assess outcome in multiple sclerosis (MS).27 As
VWM and MS are comparable in terms of white matter
involvement and chronic disease with episodic worsening,
we chose the GNDS to assess neurological function in
VWM. Nowadays, the scale is also applied in other neuro-
logical disorders.28,29 The system has proven to be reliable
when applied as a postal questionnaire.27,30 It assesses the
patient’s disability in the previous month on the basis
12 subcategories: Cognitive disability, Mood disability,
Visual disability, Speech/Communication disability, Swal-
lowing disability, Upper-limb disability (hereafter called
‘Arm’), Lower-limb disability (hereafter called ‘Leg’) Blad-
der disability, Bowel disability, Sexual Disabilities, Fatigue,
and Other Disabilities. Each domain is scored with a
6-level severity scale ranging from 0 (no disability) to
5 (maximum disability; Supplementary Table 2). A GNDS
sum score for total disability is reached by summing up all
12 subscores, with 0 for minimum and 60 for maximum
disability. We followed GNDS instructions27 for dealing
with missing values for Mood, Fatigue, and Sexual Disabil-
ities. Because of the large number of imputations for Sexual
Disability necessary for young and celibate patients, we left
this item out except for the calculation of the GNDS sum
score. For missing values in other domains, we performed
hot deck imputation as described for the HUI, up to a
number of 2 missing values. Inventories with more missing
items were excluded (5% of inventories). For Visual, Swal-
lowing, Bladder, Bowel, and Other Disabilities, we imputed
the scores in 1% of inventories.
Age at Onset Groups
We used age at onset to categorize the patients into the
following 6 groups: antenatal to early-infantile: <1 year
(1), late-infantile: 1 to <2 years (2), early-juvenile: 2 to
<4 years (3), juvenile: 4 to <8 years (4), late-juvenile to
adolescent: 8 to <18 years (5), and adult: ≥18 years (6).
Clinical disease onset was deﬁned as the age at which the
ﬁrst neurological sign had been noted retrospectively.
Clinical disease duration was deﬁned as the time from dis-
ease onset onward.
For certain analyses we preferred a less detailed sub-
division of age at onset categories; early onset: <4 years;
intermediate onset: 4 to <18 years; and late onset:
≥18 years.
Statistical Analysis
We used summary statistics to describe clinical characteris-
tics. Patient characteristics were reported by median and
quartiles and/or ranges for nonnormally distributed data.
Nominal and ordinal data were analyzed by chi-square
test, Fisher exact test, or Kruskal–Wallis test to study dif-
ferences between age-of-onset groups. We performed
time-to-event analysis of the events “disease onset,” “loss
of walking without support,” “loss of walking with or
without support,” “start of tube feeding,” “start of clear
cognitive decline,” “ﬁrst seizure,” and “death,” with age
and disease duration as two separate time variables. Indi-
viduals in whom the respective event had not occurred
were censored for the item at the latest follow-up. We esti-
mated median ages and disease durations at events by
Kaplan–Meier curves. Group differences regarding age at
onset, sex, exacerbating disease course, and affected gene
were analyzed with log-rank test. For analyses regarding
affected genes, each genotype (combination of 2 muta-
tions) was represented once. If one genotype was observed
in multiple patients, the median score was calculated by
survival analysis. We used Cox proportional hazards
models to calculate hazard ratios for predictors of survival
and loss of walking with or without support, with age at
onset as continuous variable and sex, presence of episodes,
and presence of seizures as categorical variables. Because
for the variable “seizures” the number of missing values
was considerably higher than for other variables, we per-
formed multiple imputation for this parameter, with the
other variables as predictive values, including cumulative
hazards for “loss of walking with or without support” and
“survival,” creating 5 datasets on which Cox regression
analysis was performed.
We compared HUI Health Index scores in relation
to disease duration per age at onset group via linear mixed
models, with ﬁxed effects for age at onset group and dis-
ease duration, and their 2-way interaction. Although not
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all were normally distributed, we analyzed the degree of
disability per HUI attribute and GNDS domain per age
at onset category by mean values, as this represented the
center of the 4- up to 6-level data’s distribution most
accurately.
We created spider plots using 8 selected HUI single
attribute scores and 9 selected GNDS domain scores. For
the HUI, the attribute Pain was omitted because pain was
not a prominent feature and its score was less reliable.31
For the GNDS, Fatigue, Sexual, and Other Disabilities
were omitted, because the scores were not very informa-
tive. The spider plots separately concerned mild, interme-
diate, and severe disability as assessed by the HUI Health
Index and GNDS sum scores. The values in the spider
plots represented mean scores for early (<4 years) and late
(≥18 years) age at onset patient categories. By contrasting
these 2 categories, we aimed at clearly illustrating effects
of age at onset on the different domains. The 2 categories
were compared using the independent samples t test;
p < 0.05 was considered signiﬁcant. We used linear regres-
sion to analyze the relation of GNDS sum scores and
HUI Health Index scores and comparable domain-speciﬁc
HUI and GNDS scores within patients at similar time
points. Statistical analysis was performed using SPSS ver-
sion 22 (IBM, Armonk, NY) and Prism version 6.07
(GraphPad, San Diego, CA).
Results
Patients
In total, 305 VWM patients were eligible for the study,
referred from 198 centers worldwide. Nine patients were
excluded because of comorbidity (ie, Down syndrome, bili-
ary atresia, galactosemia, glutaric aciduria type 1, encephalo-
cele and cortical dysplasia, Leigh syndrome due to LRPPRC
mutations, and perinatal asphyxia), leaving 296 patients
(134 males and 162 females) from 261 families. Genetic
analysis revealed that 5 patients had mutations in EIF2B1,
49 in EIF2B2, 23 in EIF2B3, 22 in EIF2B4, and 197 in
EIF2B5. In the case of missing data, patients were selec-
tively included in the analyses on the basis of available
information. Throughout the results section, we report the
number of patients who were included in the different ana-
lyses in parentheses or in respective tables.
Clinical and Demographic Characteristics
The age of the patients at the latest follow-up or death ran-
ged from 3 months to 62 years (median = 11 years); dis-
ease duration ranged from 1 week up to 39 years
(median = 6 years). For 63% of patients, we obtained clin-
ical questionnaires, mostly completed by physicians, in
10% by the patient and/or family members in consultation
with the authors. For the remaining patients, information
was obtained by chart review.
Patients originated from Africa (n = 1), Australia and
New Zealand (n = 11), Asia (n = 26), South America
(n = 28) North America (n = 56), and Europe (n = 174).
The database contains all known Dutch VWM patients
(n = 33); based on our numbers, the incidence in the Neth-
erlands is estimated to be 1:80,000 live births or higher.
Parental consanguinity was reported in 42 of 210 families.
Age at Onset
The distribution of age at onset was heavily skewed to the
right; for the interval 18 to 54 years, it was rather uniform
(Fig 1A). Median age at onset was 3 years (mode = 2 years,
range = before birth to 54 years). Of all patients, 87% had
onset at <18 years, 60% <4 years, 11% <1 year, and 2%
before birth. When categorizing the patients in the 6 age at
onset groups, early-juvenile (2–<4 years) onset was most
common (see Fig 1B). An overview of clinical characteris-
tics classiﬁed by age at onset group is given in Supplemen-
tary Table 3. Outline of disease course per age at onset
group is depicted in Figure 2.
Presentation
Supplementary Table 4 summarizes all presenting signs
and symptoms. Motor problems, especially gait problems,
were most common. The nature of ﬁrst signs varied for dif-
ferent ages of onset (Supplementary Table 5). Antenatal
onset was characterized by intrauterine growth retardation,
oligohydramnios, reduced fetal movements, and/or con-
tractures at birth. After birth, these patients often presented
signs of encephalopathy, with irritability, somnolence, and
seizures. Several severe, mostly infantile and early-juvenile
onset cases presented with similar signs of encephalopathy.
Loss of acquired motor skills was common among all age at
onset groups. Patients with late-juvenile, adolescent, or
adult onset more often presented with cognitive or psychi-
atric problems.
Fifty-three percent of presentations occurred after a
provoking event (see Supplementary Table 3). Infection
(often with fever) was the most common trigger (54%),
especially upper respiratory, gastrointestinal, or urinary
tract infections, inﬂuenza, otitis, and viral rashes. Mild
head trauma was the second most common trigger (44%).
Occasional triggers were vaccination and acute fright.
Seven patients were asymptomatic at study closure.
Three had not had any disease signs: one, currently 5 years
old, had been genetically tested because of an affected sib-
ling; two, currently 6 and 18 years, had been identiﬁed by
incidental ﬁndings on MRI performed because of head
trauma and headache. The other 4 patients had been iden-
tiﬁed by MRI for transient neurological signs: vertigo,
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lowered consciousness and anopia after head trauma,
unprovoked dizziness, and 1-sided vision loss. They are
currently 8, 12, 12, and 43 years old.
Early Development
Early motor development was delayed in 25% of patients
(69/276). For group 1 patients, in 47% (15/32) no
developmental problems had been noticed until subacute
deterioration. Remaining patients (53%) had mild or
severe development delay. The majority had reached some
motor milestones ranging from head control to unsup-
ported sitting, but 19% (6/32) never developed inten-
tional movements. In most group 2 patients, early motor
development was reported to be normal; 40%
FIGURE 1: Distribution of age at onset. (A) Histogram representing the number of patients per age at onset (years) for
291 vanishing white matter patients. (B) Distribution of patients per age at onset group per sex.
FIGURE 2: Disease course per age at onset group. Age at onset of vanishing white matter (VWM) and age at times of loss of
walking without support, full wheelchair dependency, start of tube feeding, and death among 291 patients are shown (numbers
of patients for each item are shown in Supplementary Table 3). The horizontal arrows range from birth to the longest follow-up
in the respective age at onset group. The numbers below the horizontal arrows indicate the median age (years) at the respective
event as estimated with the use of Kaplan–Meier curves. [Color ﬁgure can be viewed at www.annalsofneurology.org]
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(n = 20/50) had mild developmental delay. Maximum
motor milestones ranged from crawling (n = 2) to sup-
ported walking (n = 6) to unsupported walking (n = 11).
For patients of groups 3 to 6, 90% (174/194) had normal
early motor development. All 4 groups contained a few
patients with mild developmental delay (overall 10%).
Early cognitive development was abnormal in 14%
of patients, predominantly in patients with onset at
<2 years (see Supplementary Table 3).
Ambulation
Unsupported walking was achieved in no patients of
group 1, 74% of patients of group 2, and all patients of
groups 3 to 6 (see Supplementary Table 3). There were
signiﬁcant differences in age and disease duration at loss
of walking without support and wheelchair dependency
when comparing the 6 onset groups (see Supplementary
Table 3, Fig 3A). Subanalysis of groups 4, 5, and
6 revealed no signiﬁcant difference regarding disease dura-
tion at loss of walking without support (log-rank
p = 0.55) or with and without support (log-rank
p = 0.82).
Neurological Signs
Table 1 presents an overview of patients’ current status at
latest clinical inventory, subdivided for disease duration.
Spasticity and ataxia were most common. Speech was
affected in most patients, swallowing in less than half;
34% of patients received tube feeding (see Supplementary
Table 3). Vision and hearing were generally well pre-
served. Optic atrophy was reported in 17 patients but had
not been investigated systematically. Cognitive decline had
occurred in 62% of patients; it was observed earliest in
the disease course in patients with onset at <2 years and
≥18 years (see Supplementary Table 3, Fig 3B); patients
with onset at <1 year were not included in the analysis of
cognitive decline. Subanalysis of groups 4, 5, and
6 revealed that cognitive decline occurred earlier in the
disease course in group 6 than in groups 4 and 5 (log-rank
p < 0.001; see Fig 3B, right).
Seizures had occurred in 60% of patients; later dis-
ease onset was associated with lower incidence for all
groups (see Supplementary Table 3). The nature of sei-
zures was variable, including nonmotor seizures and focal
onset seizures with and without impaired awareness. Gen-
eralized onset tonic–clonic seizures were most common.
Most patients had occasional seizures, mostly well con-
trolled with medication, less often moderately controlled.
Few patients had refractory epilepsy; this was reported
most often in groups 1 and 2, and also occurred in groups
3 to 5, but never in group 6.
Mortality
Survival analysis revealed an estimated overall median sur-
vival of 38 years at a median disease duration of 24 years;
102 patients were deceased. Of deceased patients, median
age at death was 6 years (range = 3 months to 60 years)
and median disease duration at death was 3 years
(range = 1 week to 30 years). There was a signiﬁcant dif-
ference in age and duration at death for the 6 onset groups
(see Fig 3C, Supplementary Table 3). Death rate was con-
siderably higher in groups 1 to 3, in which 47% (82/174)
of patients were deceased, than for groups 4 to 6, in which
15% (18/117) had died. No signiﬁcant difference regard-
ing survival duration (log rank p = 0.77) and disease dura-
tion at death (p = 0.74) was observed between groups
4 to 6.
Deceased patients were generally at an advanced,
often vegetative stage. Respiratory failure was the leading
cause of death (61%). In a high proportion of patients,
deterioration preceding death was triggered by infection
(40%). Other causes of death were discontinuation of life
support, coma, refractory epilepsy, and cachexia.
Disease Course and Provoking Factors
Exacerbating disease course was described in 82% of
patients (see Supplementary Table 3). The median num-
ber of episodes was 3, mode = 1 (often at ﬁrst presenta-
tion), range = 1 to 25 (n = 162 patients). In 99% of
patients, episodes involved motor problems (197/198
patients), most often gait problems, ataxia, and weakness.
Cognitive function was affected in 50% (71/142 patients),
including loss of language, cognitive slowing, memory
problems, and loss of social interaction.
Sixty-two percent of patients had had one or more
episodes of coma or altered consciousness (see Supplemen-
tary Table 3). Coma and irritability were mostly observed
in patients with early onset; 87% of patients with coma
(55/63) and 92% of patients with irritability (58/63) had
onset at <8 years.
Episodes of deterioration were provoked by febrile
infections in 80% (154/193) of patients with episodes,
head trauma in 58% (106/182), and infection without
fever in 27% (42/155). Other provoking factors men-
tioned less often were anesthesia in 16% (15/92), acute
psychological stress or fright in 18% (27/150), and heat
in 5% (4/87). In many more patients, heat was stated to
adversely affect function, but in most recovery occurred
immediately after cooling down. There were incidental
reports of deterioration after the use of alcohol, sleep dep-
rivation, growth spurt, vaccination, and severe allergic
reaction. Seizures were also reported as a provoking factor,
although they may also have occurred secondary to
deterioration.
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FIGURE 3: Disease progression in relation to age at onset, episodic deterioration, and sex. Kaplan–Meier plots on (A) full
wheelchair dependency (loss of walking with or without support) in relation to age (left) and disease duration (right), per age at
onset group; (B) onset of cognitive decline in relation to age (left) and disease duration (right), per age at onset group;
(C) survival in relation to age (left) and disease duration (right), per age at onset group; (D) survival (left) and loss of walking with
or without support (right) in relation to disease duration, grouped by sex; (E) survival (left) and loss of walking with or without
support (right) in relation to disease duration, grouped by disease course with and without episodic deterioration. In all plots,
censored patients (absence of cognitive decline, still ambulant or alive at last follow-up) are indicated by crosses.
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Earlier disease onset was associated with higher sensi-
tivity to febrile infections; fever caused deterioration in
86% of patients with exacerbating disease course and
onset at <4 years versus 50% with onset at ≥18 years.
Head trauma as a provoking factor was reported with the
highest rate in patients with onset at ≥2 to <8 years (see
Supplementary Table 3).
After an episode of deterioration, patients rarely
(10%) showed complete recovery (19/183 episodes); only
few (3%; 5/183) showed almost complete recovery; the
majority of episodes (51%; 93/183) were followed by par-
tial recovery or persisting severe handicap (23%, 42/183).
In 13% (24/183), death directly followed an episode of
deterioration, most often in patients with disease onset at
<2 years.
Sex
The VWM prevalence ratio was 1:1.21 for males:females.
Imbalance was largest in the adult onset group (see Fig
1B), but statistical analysis of distribution did not reveal
signiﬁcant differences (p = 0.43). Time-to-event analysis
of survival and loss of walking without and with support
showed some differences between sexes, but these were
not statistically signiﬁcant (see Fig 3D).
Prognostic Factors
Kaplan–Meier plots indicated that exacerbating disease
course had unfavorable effects on survival and preservation
of ambulation (see Fig 3E). Multivariate Cox regression
analyses revealed that earlier age at onset, episodic deterio-
ration, and seizures had signiﬁcant positive associations
with death and loss of ambulation as independent prog-
nostic indicators, whereas there were no sex-based differ-
ences in outcome (Table 2).
Reproductive Organs
Females. In 86% of women ≥ 16 years old (48/56), signs
of ovarian failure were reported (primary or secondary
amenorrhea, irregular menses, or infertility). Ovarian dys-
genesis was found on ultrasound in 1 patient at 3 years
and at autopsy in 2 patients at 10 months and 6 years.2,32
Six women had offspring; none reported episodic deterio-
ration during or shortly after pregnancy.
Males. Except for 1 case of infertility due to oligozoos-
permia, there were no reports of involvement of reproduc-
tive organs. Of the 26 males ≥16 years old, 4 had
offspring.
Other Organs
Involvement of other organs was observed in 7 group
1 patients, including congenital cataract (n = 4), renal
hypodysplasia (n = 2), and hepatomegaly/hepatosplenome-
galy (n = 2). Several patients with disease onset at later ages
also presented diseases of other organs, but these were never
reported in >1 patient and are not considered here.
Other Features
Height was normal in 82% of patients (133/163) and
below normal in 18% (29/163, mainly with onset at
<8 years). Weight was normal in 79% (125/159), below
normal in 16% (26/159), and above normal in 5%
(8/159). Head circumference was normal in most patients
(132/169); 12% had microcephaly (21/169, mainly with
onset at <4 years), and 10% had macrocephaly (16/169,
mainly in onset groups 1–3 at advanced disease stages).
Two patients underwent ventriculoperitoneal shunting
because of suspected increased intracranial pressure, with-
out clinical improvement. Headache was the most com-
monly reported additional problem (26 patients).
Dizziness was described in 6 patients, peripheral neuropa-
thy in 3, and scoliosis in 7.
History of depression was present in 21 patients
(median age at start = 30 years, range = 12–47 years). In
23 patients, enhanced aggression, erratic behavior, or
other behavioral problems had been observed, mostly in
adulthood.
Genotype–Phenotype Correlation
Among all 296 patients, the total number of different
mutation combinations was 157. No statistically signiﬁ-
cant differences were observed for the 5 eIF2B gene
groups regarding age at onset (log rank p = 0.31) and sur-
vival (log rank p = 0.65). Only for the parameter “loss of
walking without support” was an overall signiﬁcant differ-
ence observed (log rank p = 0.025). Ambulation was bet-
ter preserved in the group of patients with EIF1B1
mutations, but this group was very small (only 5 patients)
and therefore not necessarily representative. When exclud-
ing these 5 patients from the analysis, no overall differ-
ences remained for the groups EIF2B2 to EIF2B5 (log
rank p = 0.12).
To assess the mutation-speciﬁc genotype–phenotype
correlation, we compared all available groups of at least
3 patients from different families with the same mutation
combination. In most groups of patients with similar
genotype, severity measures, such as age at onset and sur-
vival, were rather consistent, but some variability was pre-
sent, especially for mutations associated with a milder
phenotype (details in Supplementary Table 6). The homo-
zygous p.Arg113His mutation in EIF2B5 was most fre-
quent (n = 36) and most often, but not invariably,
associated with a mild phenotype.33
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TABLE 1. Status and Neurological Signs in Relation to Disease Duration
Status/Neurological Signs Overall, n = 214
Disease
Duration = 0–<5
yr, n = 83
Disease
Duration = 5–<10 y,
n = 57
Disease
Duration ≥ 10 y,
n = 74
Spasticity 82% (175/214) 75% (62/83) 79% (45/57) 92% (68/74)
Clumsiness/ataxiaa 81% (153/189) 70% (46/66) 87% (47/54) 87% (60/69)
Hypotonia 52% (69/133) 71% (41/58) 38% (13/34) 37% (15/41)
Extrapyramidal signs 28% (29/104) 25% (9/36) 26% (7/27) 32% (13/41)
Speechb
Normal 32% (58/183) 43% (24/55) 26.5% (14/53) 27% (20/75)
Dysarthria 44% (80/183) 33% (18/55) 47% (25/53) 49% (37/75)
No speech 24% (45/183) 24% (13/55) 26.5% (14/53) 24% (18/75)
Dysphagia 40% (70/177) 38% (23/60) 43% (20/47) 38% (27/70)
Vision
Normal 65% (117/181) 66% (38/58) 69% (38/55) 60% (41/68)
Decreased 26% (48/181) 24% (14/58) 22% (12/55) 33% (22/68)
Blind 9% (16/181) 10% (6/58) 9% (5/55) 7% (5/68)
Hearing
Normal 90% (158/176) 81% (45/56) 92% (47/51) 96% (66/69)
Decreased 7% (13/176) 14% (8/56) 4% (2/51) 4% (3/69)
Deaf 3% (5/176) 5% (3/56) 4% (2/51) 0% (0/69)
Cognition
Normal 38% (55/144) 56% (24/43) 42% (18/43) 22% (13/58)
Borderline functioning/mild deﬁcit 35% (50/144) 18% (8/43) 37% (18/43) 45% (26/58)
Moderate to profound deﬁcit 27% (39/144) 26% (11/43) 21% (9/43) 33% (19/58)
Current activity, children
Normal school 32% (29/90) 50% (16/32) 14% (5/36) 36% (8/22)
Special education 43% (39/90) 19% (6/32) 58% (21/36) 55% (12/22)
Learning not possible 25% (22/90) 31% (10/32) 28% (10/36) 9% (2/22)
Current activity, adults
Normal employment 14% (7/49) 33% (1/3) 43% (3/7) 8% (3/39)
Adjusted employment 12% (6/49) 0% (0/3) 14% (1/7) 13% (5/39)
Daycare 45% (22/49) 67% (2/3) 29% (2/7) 46% (18/39)
Bedridden 29% (14/49) 0% (0/3) 14% (1/7) 33% (13/39)
aNine patients were left out as coordination was not evaluable due to absence of intentional movements.
bScored in patients from 2 years of age.
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Intrafamilial Variation
Thirty-three families had >1 affected child. Siblings from
18 families were categorized in the same onset group. In
the other 15 families, siblings were categorized in 2 subse-
quent onset groups. Disease course and severity among
siblings were relatively similar. Siblings with disease onset
at <2 years all showed homogeneous phenotypes with
rapid deterioration. With childhood or adult onset, wider
individual variation was observed and siblings could show
more divergent phenotypes with involvement of different
domains.
Disability Scores
An overview is provided in Supplementary Table 7A. In
total, 262 patients were eligible for formal HUI scoring
based on the age criterion of ≥2 years. We obtained at
least 1 formal HUI inventory in 65% of patients
(171/262) at disease durations ranging from 6 months to
38 years. In several patients, >1 HUI inventory was per-
formed, bringing the total number to 258.
For GNDS scoring, 178 patients were eligible based
on the age criterion of ≥8 years. In 64% of patients
(114/178), at least 1 GNDS inventory was obtained at
disease durations ranging from 1 to 38 years. In several
patients, >1 GNDS inventory was performed, bringing
the total number to 172.
HUI Health Index
The overall median HUI Health Index score derived from
formal assessments across all time points was 0.21 (quar-
tiles = −0.14 to 0.69). Thirty-six percent of scores
(93/258) were negative. We also gave all patients a stan-
dard baseline score at disease onset and all deceased
patients a score of −0.5 at death. In 60 patients, no formal
HUI scoring was obtained; they only received baseline
and death scores. The disease course per patient on the
basis of all HUI scores from disease onset until latest
follow-up or death is depicted in Figure 4A. There was a
wide variability in disease course, but later onset was gen-
erally associated with less disability and lower mortality.
The HUI Health Index scores per onset group in relation
to disease duration are depicted in Figure 4B and show a
wide variability. Analysis at group level by linear mixed
model analysis showed that the course of the scores dif-
fered signiﬁcantly between the age at onset groups
(p < 0.001). Disease progression was most rapid in group
1, followed by group 2, subsequently group 3, and then
groups 4 to 6. There were no signiﬁcant differences
between groups 4, 5, and 6.
HUI Single-Attribute Scores
The distribution of scores per HUI attribute is displayed
in Supplementary Table 7B. Dependent on age at onset,
there were differences in the distribution of disability
TABLE 2. Multivariate Cox Regression Analyses of Factors Affecting Survival and Loss of Walking with or
without Support
Factor Survival Preservation of Ambulation
n Hazard Ratio (95% CI) p n Hazard Ratio (95% CI) p
Age at onset
Continuous variable 259 1.07 (1.02–1.13) 0.009 213 1.05 (1.01–1.09) 0.008
Sex
Male 118 1.0, reference 0.28 95 1.0, reference 0.53
Female 141 1.26 (0.83–1.93) 118 1.13 (0.78–1.64)
Exacerbating course
Absent 46 1.0, reference 0.033 40 1.0, reference 0.001
Present 213 0.33 (0.12 –0.91) 173 0.25 (0.11–0.56)
History of seizuresa
Absent 97 1.0, reference 0.016 88 1.0, reference <0.001
Present 162 0.42 (0.21–0.85) 125 0.27 (0.16–0.45)
aInformation was imputed for 75 patients.
CI = conﬁdence interval.
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scores at different stages of the disease. We therefore made
spider plots presenting the distribution of HUI single
attribute scores for early and late onset categories and sep-
arately for mild, intermediate, and severe disability, as
assessed by overall HUI Health Index scores (Fig 5). For
mild disability, early onset was typically associated with
motor signs, whereas late onset patients more often
presented cognitive problems. At the intermediate disabil-
ity stage, motor problems were already severe in early
onset patients. In the case of severe disability, profound
motor problems, loss of self-care, and moderate to severe
cognitive decline was invariably present in early and late
onset categories. Hearing and Emotion were generally
spared. Mean scores and conﬁdence intervals of all
FIGURE 4: Disease course in vanishing white matter patients as assessed by Health Utilities Index (HUI) Health Index scores.
Graphs depict disease course in relation to age (A) and disease duration (B). One line represents 1 patient. Age at onset groups
are marked by different colors. Scores range from −0.50 (dead) to 1 (perfectly healthy). Solid lines represent patients in whom
≥1 formal scores were obtained. Dotted lines represent patients in whom only baseline and death scores were available. In some
patients, the score initially improves as a result of a better score at the ﬁrst formal assessment compared to the standard
baseline score.
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HUI attributes for all 3 onset categories are available at
https://www.vumc.com/branch/Children-White-Matter-
Disorders.
Quality of Life: Impact on Emotion
Considering the large number of negative formal HUI
Health Index scores (n = 93), a state considered worse
than dead by the general population, we evaluated the
scores on the HUI attribute Emotion (Fig 6). In total,
only 8 of 258 Emotion scores represented a state “so
unhappy that life is not worthwhile.”
Guy’s Neurological Disability Scale
The overall median GNDS sum score across all time points
was 21 (quartiles = 10–33). The distribution of scores per
GNDS domain is displayed in Supplementary Table 7C.
We again made spider plots to depict the distribution of
GNDS domain scores for the early and the late onset cate-
gories and separately for mild, intermediate, and severe dis-
ability, as assessed by the GNDS sum score (Fig 5). Early
onset cases typically presented motor signs at early disease
stages, whereas late onset patients more often presented
cognitive problems early in the disease course. Speech/
Communication was better preserved in late onset cases.
Mood was relatively spared among early onset cases. Mean
scores and conﬁdence intervals of all GNDS domain scores
for the 3 onset categories are available at https://www.
vumc.com/branch/Children-White-Matter-Disorders.
Other Problems
In 51% of the questionnaires (87/172), other problems
due to VWM were mentioned in addition to the
FIGURE 5: Spider plots of selected Health Utilities Index (HUI) and Guy’s Neurological Disability Scale (GNDS) scores in the early
and late age at onset categories. Mean HUI single attribute scores and GNDS domain scores are shown for 3 different disease
stages for early (<4 years, black lines) and late (≥18 years, orange lines) onset vanishing white matter. (A–C) HUI Health Index scores
of ≥0.5 to 1.0 represent mild to no disability (A), scores of 0 to < 0.5 represent intermediate disability (B), and scores of −0.36 to
0 represent severe disability (C). HUI attribute scores range from 0.0 (most disabled) to 1.0 (normal status). (D–F) GNDS sum score
<10 represents mild disability (D), score = 10 to <30 represents intermediate disability (E), and score ≥ 30 represents severe
disability (F). GNDS domain scores range from 0 (normal status) to 5 (total loss of function). HUI attributes and GNDS domains in
which the scores of the early and late age at onset categories are signiﬁcantly different are indicated by *p < 0.05, **p < 0.01, and
***p < 0.001. In the plots of GNDS scores, the order of domains was based on the order of the items in the questionnaires. The
order of the HUI domains was adapted to create analogy with the GNDS spider plots for overlapping items. For the HUI, a higher
score is associated with better function, whereas for the GNDS a higher score is associated with worse function.
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11 GNDS domains. Details are available in Supplemen-
tary Table 7D.
Correlation HUI and GNDS Scores
Comparison of HUI Health Index and GNDS sum scores
for individuals revealed a signiﬁcant correlation (p < 0.001,
r2 = 0.82). Comparison of scores on domains that were
covered by both systems, obtained in individuals at the
same time points, showed a signiﬁcant correlation for all
domains (p < 0.001), Cognition (r2 = 0.57), Vision
(r2 = 0.69), Speech/Communication (r2 = 0.57), Leg
Function (r2 = 0.78), and Arm Function (r2 = 0.77).
Discussion
Our study conﬁrms that VWM has an extremely broad
phenotypic range and that age at onset is an important
determinant of prognosis.15,34 Patients with onset at
<1 year consistently have a rapidly progressive disease and
die within several months. They rarely show any recovery
after episodic deterioration. Many are encephalopathic and
have refractory epilepsy. Involvement of extracerebral
organs occurs only in this group. Patients with onset at
1 to <2 years typically show rapid decline, with wheelchair
dependency after months to a few years and often death
after several years. Disease course in patients with onset at
2 to <4 years is more variable, but generally fairly progres-
sive. Many die after 1 to several years, but others reach
adulthood, although invariably severely handicapped. No
signiﬁcant differences in rates of deterioration are present
between patients with onsets at 4 to <8, 8 to <18, and
≥18 years; mortality is low. Patients with onset at
≥18 years are more likely to have cognitive decline early in
the diseases course.
Thus, within the VWM spectrum, 2 key disease
courses can be distinguished: presentation at <4 years
(60% of cases in our cohort) is generally followed by a
rapidly progressive course dominated by motor dysfunc-
tion with a profound age at onset effect on disease course.
Presentation from 4 years on (40%) is associated with a
more heterogeneous, less progressive course with low mor-
tality, independent of age at onset. These are not strictly
separated phenotypes, and much variation is seen, with
some early onset patients having an unexpectedly slow dis-
ease course and some late onset patients experiencing
rapid decline and death. For most leukodystrophies, later
age at onset is associated with slower clinical progres-
sion.35 It is interesting that in VWM, apart from the lon-
ger symptom-free interval, presentation in adulthood is
not associated with a more favorable disease course than
presentation in later childhood or adolescence. For all ages
of onset, seizures and episodic deteriorations are important
negative predictors of disease course, underlining the
importance of seizure control and preventive measures
such as avoiding head trauma, antibiotics, and antipyretics
for all patients.7 The present study conﬁrms the presence
of a genotype–phenotype correlation.15,33,36
In patients with severe phenotypes, the genotype
appears to supersede the effect of environmental or other
genetic factors on the symptomatology, whereas in milder
variants, larger variability is observed, most likely due to
the impact of environment, such as exposure to factors
that provoke episodic deterioration.
Prior studies have pointed to sex-related differences
among VWM patients, such as the male:female imbalance
among adolescent/adult onset patients and possible differ-
ences in disease severity.13,14,33 Our study did not conﬁrm
consistent clinical differences between males and females.
Although we also observed an overrepresentation of females
among adult onset cases, this ﬁnding was not statistically
signiﬁcant. Still larger numbers of patients are required to
deﬁnitively address the question of sex differences in VWM.
Using the HUI and GNDS, we estimated disability
in VWM patients with different ages at onset and disease
courses in a standardized way. The scores provide insight
into proﬁles of sequential loss of function. The domains
ambulation and manual dexterity are most severely
affected. The majority of patients are dependent on carers
for eating, bathing, dressing, and/or toilet use. Over time,
loss of bladder and bowel function occurs, and at
advanced disease stage speech and swallowing are affected.
Compared to children, who soon have prominent motor
handicap, adult onset patients show earlier and more
prominent cognitive problems, as commonly observed in
FIGURE 6: Individuals’ Health Utilities Index Mark 3 (HUI3)
Emotion scores in relation to their formal HUI Health Index
scores, which range from −0.36 (most disabled state) to
1 (no handicap). 1 = happy and interested in life;
2 = somewhat happy; 3 = somewhat unhappy; 4 = very
unhappy; 5 = so unhappy that life is not worthwhile.
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leukodystrophies in general,37 and more often have pre-
served speech in advanced disease. Vision and hearing
remain relatively intact in all patients.
The attribute utility scores of the HUI not only rep-
resent a measure of health status, but also embody the
subjective views of society on objectively deﬁned health
status features, as obtained from a random sample of
504 people from Canada.23 Remarkably, despite one-third
of HUI Health Index scores representing a “worse than
dead” health state, most patients were perceived as
“happy” or “somewhat happy” (scores on the attribute
Emotion). Clearly, society’s perspective may not corre-
spond to the quality of life perceived by patients or their
caregivers, a phenomenon known as “disability para-
dox.”38 As has been observed in other debilitating neuro-
logical disorders,39,40 patients often adjust their subjective
perception of quality of life. This change of internal stan-
dards or “response-shift”41 is not represented in the HUI.
In the majority of patients, the responses were generated
by parents and health professionals, who tend to provide
lower valuations for HRQL than patients,39,42,43 suggest-
ing that the discrepancy between HRQL as perceived by
patients and as perceived by society may even be greater.
No agreement exists on how to do justice to both the
objective function and the subjective judgment of HRQL.
This study has some limitations. We aimed for robust
parameters of disease progression. However, certain parame-
ters, such as wheelchair dependency, may be inﬂuenced by
factors such as motivation. For survival, differences in clinical
practice, medical resources, and cultural preferences regarding
end stage disease impact outcome. Several items were scored
by subjective assessment; without formal testing, parameters
such as cognitive decline, vision, and hearing are rather
rough indicators of the respective items. Interobserver differ-
ences and selection and information biases may have ham-
pered the study. In natural history studies, assessments
would optimally be prospective and occur at regular intervals
from disease onset until death in all patients. Death and loss
to follow-up caused numerous missing data in all patient
groups. We have no evidence that nonresponse was in any
way systematic. As a result of the multicenter nature of the
study and the wide variability in disease course, we had to
deal with different intervals for the clinical scoring, incom-
plete datasets, censored data, and survival effects, with longer
follow-up and therefore more follow-up data on patients
with milder disease course; survival analysis and mixed model
linear analysis are the appropriate statistical methods to ana-
lyze such datasets and are applied here.
This study also has important strengths. Most limi-
tations mentioned are lessened or overcome by the large
number of patients for a rare disease, enhancing the power
of the study and compensating for missing data. Other
strengths are the longitudinal character of the study, with
duration of 12½ years, and the use of standardized instru-
ments that have been extensively validated in diverse
populations.18,27,30,44,45 The latter also enables the com-
parison of the burden of VWM to other patient groups.
Overall, this study provides robust insights into domains
of disability in VWM for different age at onset groups.
The study results are important for health services,
as type and severity of disability determine patients’ capa-
bilities to perform daily activities, type and level of care
needed, and social and economic impact of the disease.
Additionally, estimates derived from natural history are
crucial for study design of clinical trials, selection of clini-
cally relevant endpoints, and determination of which
patient population to target. There are currently no cura-
tive treatment options for VWM, but the technological
progress in the ﬁeld of leukodystrophies is promising.46,47
Prospects of curative therapy have intensiﬁed the need to
document the natural history of VWM. In this view, the
current work may serve as a reference point to design and
evaluate future therapeutic interventions.
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